In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy

Regardless of the recent advances in cytotoxic therapies, 30% of children diagnosed with medulloblastoma. succumb to the disease. Therefore, novel therapeutic approaches are warranted. Here we demonstrate that Pazopanib a clinically approved multi-kinase angiogenesis inhibitor (MKI) inhibits prolife...

Descripción completa

Detalles Bibliográficos
Autores principales: Craveiro, Rogerio B., Ehrhardt, Michael, Holst, Martin I., Pietsch, Thorsten, Dilloo, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196191/
https://www.ncbi.nlm.nih.gov/pubmed/25216529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196191/
https://www.ncbi.nlm.nih.gov/pubmed/25216529

Ejemplares similares